Temozolomide Patent Expiration
Temozolomide is Used for treating malignant neoplasms. It was first introduced by Merck Sharp And Dohme Corp
Temozolomide Patents
Given below is the list of patents protecting Temozolomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Temodar | US6987108 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
Sep 08, 2023
(Expired) | Merck Sharp Dohme |
| Temodar | US7786118 | Pharmaceutical formulations of antineoplastic agents |
Feb 21, 2023
(Expired) | Merck Sharp Dohme |
| Temodar | US8623868 | Processes of making and using pharmaceutical formulations of antineoplastic agents |
Feb 21, 2023
(Expired) | Merck Sharp Dohme |
| Temodar |
US5260291 (Pediatric) | Tetrazine derivatives |
Feb 11, 2014
(Expired) | Merck Sharp Dohme |
| Temodar | US5260291 | Tetrazine derivatives |
Aug 11, 2013
(Expired) | Merck Sharp Dohme |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Temozolomide's patents.
Latest Legal Activities on Temozolomide's Patents
Given below is the list recent legal activities going on the following patents of Temozolomide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jan, 2022 | US7786118 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2018 | US7786118 |
| Correspondence Address Change Critical
| 26 Aug, 2011 | US7786118 |
| Correspondence Address Change Critical
| 26 Aug, 2011 | US6987108 |
| Post Issue Communication - Certificate of Correction | 09 Feb, 2011 | US7786118 |
| Recordation of Patent Grant Mailed Critical
| 31 Aug, 2010 | US7786118 |
| Patent Issue Date Used in PTA Calculation Critical
| 31 Aug, 2010 | US7786118 |
| Issue Notification Mailed Critical
| 11 Aug, 2010 | US7786118 |
| Application Is Considered Ready for Issue Critical
| 03 Aug, 2010 | US7786118 |
| Dispatch to FDC | 03 Aug, 2010 | US7786118 |
Temozolomide's Family Patents
